Last reviewed · How we verify
Oral Maalox/ Mylanta
Maalox/Mylanta neutralizes gastric acid and reduces acid reflux symptoms through a combination of aluminum hydroxide, magnesium hydroxide, and simethicone.
Maalox/Mylanta neutralizes gastric acid and reduces acid reflux symptoms through a combination of aluminum hydroxide, magnesium hydroxide, and simethicone. Used for Heartburn and acid indigestion, Gastroesophageal reflux disease (GERD) symptom relief, Upset stomach and bloating.
At a glance
| Generic name | Oral Maalox/ Mylanta |
|---|---|
| Also known as | Antacid |
| Sponsor | Stony Brook University |
| Drug class | Antacid combination |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
Aluminum hydroxide and magnesium hydroxide are antacids that directly neutralize hydrochloric acid in the stomach, raising gastric pH and reducing acid-related irritation. Simethicone is an antifoaming agent that reduces gas bubbles in the gastrointestinal tract, alleviating bloating and discomfort associated with acid reflux and indigestion.
Approved indications
- Heartburn and acid indigestion
- Gastroesophageal reflux disease (GERD) symptom relief
- Bloating and gas associated with indigestion
Common side effects
- Constipation (aluminum hydroxide)
- Diarrhea (magnesium hydroxide)
- Nausea
- Abdominal cramping
Key clinical trials
- Famotidine and Antacids for Treatment of Dyspepsia (PHASE4)
- Effects of Photobiomodulation (PBM) on Pain After Presentation of Aphthous Ulcers in Pediatric Dental Patients (PHASE4)
- A Study of the Drug Interactions Between Danicopan and Cyclosporine, Tacrolimus, Antacids, and Omeprazole in Healthy Adults (PHASE1)
- Study to Examine the Effect of Antacid and Omeprazole on the Single-Dose Pharmacokinetics of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Healthy Adult Subjects (PHASE1)
- Effect of Antacids on the Pharmacokinetics of Raltegravir (PHASE1)
- A Pharmacokinetic Study to Evaluate the Effect of Antacids on Raltegravir (MK-0518) in HIV-Infected Participants (MK-0518-247) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oral Maalox/ Mylanta CI brief — competitive landscape report
- Oral Maalox/ Mylanta updates RSS · CI watch RSS
- Stony Brook University portfolio CI